ARCH Venture Partners

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative parenteral medical countermeasure drugs, particularly tezampanel, for treating seizures and brain injuries. Founded in 2016, the company has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving exposure to soman, a highly toxic chemical weapon. By targeting the central nervous system, Proniras aims to develop novel small-molecule therapeutics for various neurological conditions characterized by high unmet medical needs. Their research is designed to provide medical researchers with valuable tools for advancing treatments in this critical area.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Arivale Inc. is a wellness services provider that focuses on helping individuals optimize their health and prevent diseases through a scientific approach. Founded in 2014 and headquartered in Seattle, Washington, the company analyzes various aspects of an individual's health, including genetics, blood markers, microbiome data, and lifestyle choices. By combining this personalized data with tailored coaching and support from a clinical team, Arivale delivers actionable recommendations to enhance wellness. Their program not only empowers individuals to make informed decisions regarding diet and exercise but also contributes to a longitudinal dataset that aids in the discovery of innovative health improvement methods. Overall, Arivale is dedicated to providing a comprehensive and intimate view of well-being to enhance the quality of life for its members.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell-based immunotherapies for cancer treatment. Utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies, Juno engineers T cells to target and eliminate cancer cells. The company's product pipeline includes several promising candidates, such as JCAR017, in Phase I/II trials for relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, as well as JCAR018 for pediatric patients with CD22-positive cancers. Other candidates target various malignancies, including neuroblastoma, lung cancer, ovarian cancer, and glioblastoma. Juno collaborates with leading cancer research institutions to advance its therapies and was founded in 2013, headquartered in Seattle, Washington. In 2018, Juno became a subsidiary of Bristol-Myers Squibb Company.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell-based immunotherapies for cancer treatment. Utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies, Juno engineers T cells to target and eliminate cancer cells. The company's product pipeline includes several promising candidates, such as JCAR017, in Phase I/II trials for relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, as well as JCAR018 for pediatric patients with CD22-positive cancers. Other candidates target various malignancies, including neuroblastoma, lung cancer, ovarian cancer, and glioblastoma. Juno collaborates with leading cancer research institutions to advance its therapies and was founded in 2013, headquartered in Seattle, Washington. In 2018, Juno became a subsidiary of Bristol-Myers Squibb Company.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

PhaseRx is a Seattle-based biopharmaceutical startup focused on developing intracellular enzyme replacement therapies for inherited liver diseases using its proprietary Hybrid mRNA Technology platform. This platform enables the synthesis of missing enzymes within cells, targeting three urea cycle disorders: ornithine transcarbamylase deficiency (OTCD), argininosuccinate lyase deficiency (ASL deficiency), and argininosuccinate synthetase deficiency (ASS1 deficiency). The company was founded by industry veterans and renowned academics, attracting top-tier venture capital investments.

Allozyne, Inc. is a biopharmaceutical company focused on developing novel protein therapeutic product candidates aimed at treating autoimmune and inflammatory diseases, as well as cancer. Founded in 2004 and headquartered in Seattle, Washington, Allozyne is known for its lead product candidate, AZ01, which is currently in Phase 1b clinical trials for relapsing-remitting multiple sclerosis. The company is also advancing AZ17, a bispecific antibody targeting various autoimmune and inflammatory conditions, including Crohn's disease and multiple sclerosis, and AZ05, an antibody-drug conjugate designed for treating solid tumors. Additionally, Allozyne specializes in the development of technologies that enhance the efficacy, safety, and dosing of protein-based therapeutics, including peptides and antibodies. The company operates as a subsidiary of Poniard Pharmaceuticals, Inc.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Theraclone Sciences, Inc. is a discovery-stage biotechnology company based in Seattle, Washington, focused on developing novel therapeutic antibodies for cancer and infectious diseases. The company employs its proprietary In-Situ Therapeutic Antibody Rescue technology to rapidly identify and test human antibodies with exceptional biological functions. Theraclone's pipeline includes TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza, along with several preclinical and clinical programs targeting unmet medical needs such as triple-negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Founded in 2004 and originally known as Spaltudaq Corporation until its rebranding in 2009, Theraclone leverages the natural immune responses of human subjects to discover rare monoclonal antibodies that could lead to effective therapeutic interventions.

Allozyne, Inc. is a biopharmaceutical company focused on developing novel protein therapeutic product candidates aimed at treating autoimmune and inflammatory diseases, as well as cancer. Founded in 2004 and headquartered in Seattle, Washington, Allozyne is known for its lead product candidate, AZ01, which is currently in Phase 1b clinical trials for relapsing-remitting multiple sclerosis. The company is also advancing AZ17, a bispecific antibody targeting various autoimmune and inflammatory conditions, including Crohn's disease and multiple sclerosis, and AZ05, an antibody-drug conjugate designed for treating solid tumors. Additionally, Allozyne specializes in the development of technologies that enhance the efficacy, safety, and dosing of protein-based therapeutics, including peptides and antibodies. The company operates as a subsidiary of Poniard Pharmaceuticals, Inc.

Integrated Diagnostics Inc. is a company focused on developing laboratory-based blood diagnostic tools that facilitate the early diagnosis of complex diseases through non-invasive blood tests. Established in 2005 and headquartered in Seattle, Washington, the company specializes in products that monitor multiple molecular markers simultaneously, offering valuable insights for conditions such as lung cancer. One of its key offerings is Xpresys Lung, a molecular blood test designed to provide objective information for assessing pulmonary nodules. Integrated Diagnostics is committed to leveraging advanced technologies to create a pipeline of innovative diagnostic products aimed at enhancing disease management for conditions including cancer, diabetes, and Alzheimer's. The company operates under a strategic partnership with Agilent Technologies Inc. and has been functioning as a subsidiary of Biodesix, Inc. since 2018.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Viathan Corporation specializes in developing software infrastructure for storage environments, focusing on data management solutions. The company offers a virtual storage system that enables the aggregation of various storage devices, enhancing efficiency for businesses and e-commerce vendors. Founded in February 1999 and based in Seattle, Washington, Viathan was acquired by Dantz Development in October 2001. Its technology aims to streamline data management processes, making it a valuable asset for organizations looking to optimize their storage capabilities.

Appliant.com is a technology company specializing in web monitoring solutions that assess infrastructure and application performance, availability, and usage with an emphasis on enhancing customer experience. Established in 1997 in Seattle, the company serves e-businesses, enterprises, and service providers, helping them optimize their investments in web applications and infrastructure. Appliant.com offers its services as an Application Service Provider (ASP) solution through its Lateral Line Network, which utilizes a network of unobtrusive monitors deployed across the Internet. This system captures real-time data from actual users, providing clients with a comprehensive view of their website's performance and usage. Appliant.com remains privately held and continues to be a leader in its field.

ProjectGuides.com is an online marketplace that connects buyers and sellers of professional services in the architectural, engineering, and environmental sectors. The company utilizes advanced qualifications-based search technology to match professionals with public and private sector opportunities. By continuously scanning over 5,000 electronic and print sources, ProjectGuides.com provides its subscribers with a robust stream of leads, delivering approximately 3,000 opportunities weekly. This platform enables service providers to access a customized source of business leads, resulting in billions of dollars in annual business opportunities. Headquartered in Bellevue, Washington, ProjectGuides.com is a rapidly growing private company that aims to transform the way the professional service industry operates in both the built and natural environments.

Classmates, Inc., established in 1995 and headquartered in Seattle, Washington, operates the leading online social network in the United States for high school alumni. The company's platform enables users to find, reconnect, and stay connected with their high school classmates, plan and attend reunions, and share memories through its extensive library of digitized yearbooks. As of 2015, Classmates serves over 70 million members, making it a significant player in the alumni networking space.

ProjectGuides.com is an online marketplace that connects buyers and sellers of professional services in the architectural, engineering, and environmental sectors. The company utilizes advanced qualifications-based search technology to match professionals with public and private sector opportunities. By continuously scanning over 5,000 electronic and print sources, ProjectGuides.com provides its subscribers with a robust stream of leads, delivering approximately 3,000 opportunities weekly. This platform enables service providers to access a customized source of business leads, resulting in billions of dollars in annual business opportunities. Headquartered in Bellevue, Washington, ProjectGuides.com is a rapidly growing private company that aims to transform the way the professional service industry operates in both the built and natural environments.